Restoration of TP53 strategy via specific nanoparticles for ovarian cancer therapy
Abstract The p53 tumor suppressor gene, a master regulator of diverse cellular pathways, is frequently altered in various cancers. Loss of function in tumor suppressor genes is commonly associated with the onset/progression of cancer and treatment resistance. Currently, approaches for restoration of...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Journal of Ovarian Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13048-025-01672-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849729134251474944 |
|---|---|
| author | Menglei Zhang Yuanyuan Gu Fang Shen Yingxin Gong Zheng Gu Keqin Hua Guannan Zhou Jingxin Ding |
| author_facet | Menglei Zhang Yuanyuan Gu Fang Shen Yingxin Gong Zheng Gu Keqin Hua Guannan Zhou Jingxin Ding |
| author_sort | Menglei Zhang |
| collection | DOAJ |
| description | Abstract The p53 tumor suppressor gene, a master regulator of diverse cellular pathways, is frequently altered in various cancers. Loss of function in tumor suppressor genes is commonly associated with the onset/progression of cancer and treatment resistance. Currently, approaches for restoration of TP53 expression, including small molecules and DNA therapies, have yielded progressive success, but each has formidable drawbacks. Here, we introduced an endogenous nanoplatform to effectively deliver the TP53 protein. Briefly speaking, the endogenous TP53 proteins were fused by the Lamp2b and loaded into extracellular vesicles-based nanoparticles, which could markedly restore the TP53 expression in natural TP53-deficient ovarian cancer (OCs) and subsequently inhibit cell proliferation as well as induce cell apoptosis. Moreover, a well-known biotin streptavidin binding strategy was used to confer the nanoplatform targeting ability. Since mesothelin (MSLN) expressed highly in ovarian cancer, the anti-MSLN nanoplatform were engineered to deliver TP53 proteins to MSLN ovarian cancer and exert the anti-tumor ability. Our findings indicated that restoration of tumor suppressors by the targeting nanoplatform could be promising nanotechnology approaches for potential ovarian cancer treatment. |
| format | Article |
| id | doaj-art-cfdb05ff254e45ef88c984448656daf9 |
| institution | DOAJ |
| issn | 1757-2215 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Ovarian Research |
| spelling | doaj-art-cfdb05ff254e45ef88c984448656daf92025-08-20T03:09:19ZengBMCJournal of Ovarian Research1757-22152025-05-0118111610.1186/s13048-025-01672-9Restoration of TP53 strategy via specific nanoparticles for ovarian cancer therapyMenglei Zhang0Yuanyuan Gu1Fang Shen2Yingxin Gong3Zheng Gu4Keqin Hua5Guannan Zhou6Jingxin Ding7Department of Gynecology, The Obstetrics and Gynecology Hospital of Fudan UniversityDepartment of Gynecology, The Obstetrics and Gynecology Hospital of Fudan UniversityDepartment of Gynecology, The Obstetrics and Gynecology Hospital of Fudan UniversityDepartment of Gynecology, The Obstetrics and Gynecology Hospital of Fudan UniversityDepartment of Gynecology, The Obstetrics and Gynecology Hospital of Fudan UniversityDepartment of Gynecology, The Obstetrics and Gynecology Hospital of Fudan UniversityDepartment of Gynecology, The Obstetrics and Gynecology Hospital of Fudan UniversityDepartment of Gynecology, The Obstetrics and Gynecology Hospital of Fudan UniversityAbstract The p53 tumor suppressor gene, a master regulator of diverse cellular pathways, is frequently altered in various cancers. Loss of function in tumor suppressor genes is commonly associated with the onset/progression of cancer and treatment resistance. Currently, approaches for restoration of TP53 expression, including small molecules and DNA therapies, have yielded progressive success, but each has formidable drawbacks. Here, we introduced an endogenous nanoplatform to effectively deliver the TP53 protein. Briefly speaking, the endogenous TP53 proteins were fused by the Lamp2b and loaded into extracellular vesicles-based nanoparticles, which could markedly restore the TP53 expression in natural TP53-deficient ovarian cancer (OCs) and subsequently inhibit cell proliferation as well as induce cell apoptosis. Moreover, a well-known biotin streptavidin binding strategy was used to confer the nanoplatform targeting ability. Since mesothelin (MSLN) expressed highly in ovarian cancer, the anti-MSLN nanoplatform were engineered to deliver TP53 proteins to MSLN ovarian cancer and exert the anti-tumor ability. Our findings indicated that restoration of tumor suppressors by the targeting nanoplatform could be promising nanotechnology approaches for potential ovarian cancer treatment.https://doi.org/10.1186/s13048-025-01672-9NanoplatformTP53Ovarian cancerTargetingEngineering |
| spellingShingle | Menglei Zhang Yuanyuan Gu Fang Shen Yingxin Gong Zheng Gu Keqin Hua Guannan Zhou Jingxin Ding Restoration of TP53 strategy via specific nanoparticles for ovarian cancer therapy Journal of Ovarian Research Nanoplatform TP53 Ovarian cancer Targeting Engineering |
| title | Restoration of TP53 strategy via specific nanoparticles for ovarian cancer therapy |
| title_full | Restoration of TP53 strategy via specific nanoparticles for ovarian cancer therapy |
| title_fullStr | Restoration of TP53 strategy via specific nanoparticles for ovarian cancer therapy |
| title_full_unstemmed | Restoration of TP53 strategy via specific nanoparticles for ovarian cancer therapy |
| title_short | Restoration of TP53 strategy via specific nanoparticles for ovarian cancer therapy |
| title_sort | restoration of tp53 strategy via specific nanoparticles for ovarian cancer therapy |
| topic | Nanoplatform TP53 Ovarian cancer Targeting Engineering |
| url | https://doi.org/10.1186/s13048-025-01672-9 |
| work_keys_str_mv | AT mengleizhang restorationoftp53strategyviaspecificnanoparticlesforovariancancertherapy AT yuanyuangu restorationoftp53strategyviaspecificnanoparticlesforovariancancertherapy AT fangshen restorationoftp53strategyviaspecificnanoparticlesforovariancancertherapy AT yingxingong restorationoftp53strategyviaspecificnanoparticlesforovariancancertherapy AT zhenggu restorationoftp53strategyviaspecificnanoparticlesforovariancancertherapy AT keqinhua restorationoftp53strategyviaspecificnanoparticlesforovariancancertherapy AT guannanzhou restorationoftp53strategyviaspecificnanoparticlesforovariancancertherapy AT jingxinding restorationoftp53strategyviaspecificnanoparticlesforovariancancertherapy |